Author:
Lee Jung-Hee,Lee Je-Hwan,Kim Dae-Young,Kim Sung-Doo,Choi Yunsuk,Kang Young-Ah,Seol Miee,Lee Kyoo-Hyung
Subject
Hematology,General Medicine
Reference31 articles.
1. Proteasome inhibitors: a novel class of potent and effective antitumor agents;Adams;Cancer Res,1999
2. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents;Ma;Clin Cancer Res,2003
3. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells;Hideshima;Cancer Res,2001
4. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma;Oakervee;Br J Haematol,2005
5. Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients;Palumbo;J Clin Oncol,2010